Correcting Smad1/5/8, mTOR, and VEGFR2 treats pathology in hereditary hemorrhagic telangiectasia models.
Ruiz S, Zhao H, Chandakkar P, Papoin J, Choi H, Nomura-Kitabayashi A, Patel R, Gillen M, Diao L, Chatterjee PK, He M, Al-Abed Y, Wang P, Metz CN, Oh SP, Blanc L, Campagne F, Marambaud P.
Ruiz S, et al. Among authors: marambaud p.
J Clin Invest. 2020 Feb 3;130(2):942-957. doi: 10.1172/JCI127425.
J Clin Invest. 2020.
PMID: 31689244
Free PMC article.